ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR | NASDAQ
Chart Builder DCF Calculator
$1.88
+$0.02 (+1.08%)
Sep 22, 2026, 12:35 PM ET · Market open

Market Data

Market Cap
$195.87M
Enterprise Value
$67.6M
Beta
0.03
Average Volume
942.8K
Shares Outstanding (Diluted)
109.96M
Shares Change YoY
4.38%
Institutional Ownership
33.30%
Exchange
NASDAQ
ISIN
NL0010872495

Price Performance

Price Change 1M
-20.9%
Price Change 3M
-1.6%
Price Change 6M
17.7%
Price Change YTD
-6.5%
Price Change 1Y
-13.9%
Price Change 3Y
26.5%
Price Change 5Y
-76.1%
1M CAGR (ann.)
-1.1%
1Y CAGR (ann.)
-15.1%
5Y CAGR (ann.)
-26.0%
All-Time CAGR
-15.8%

Valuation

PE Ratio
-3.99
Forward PE
N/A
PEG Ratio
-0.71
Forward PEG
-0.25
PS Ratio
9.04
Forward PS
8.70
PB Ratio
2.16
P/FCF Ratio
-3.34
P/Adj. FCF Ratio
-3.11
P/OCF Ratio
-3.54
EV/Sales
3.64
EV/EBIT
-1.67
EV/EBITDA
-1.79
EV/FCF
-1.34
Earnings Yield
-24.6%
FCF Yield
-29.4%
Adj. FCF Yield
-31.6%

Financial Health

Net Cash
€112.58M
Total Debt
€13.19M
Cash & Short-Term Investments
€117.08M
Total Assets
€133.5M
Current Ratio
3.49
Quick Ratio
3.49
Debt / Equity Ratio
0.17
Debt / EBITDA
-0.35
Debt / FCF
-0.26
OCF / Debt
-3.73
Interest Coverage
0.00
Altman Z-Score
-3.29
Piotroski F-Score
1

Margins & Profitability

Gross Profit Margin
92.3%
Operating Profit Margin
-232.7%
EBITDA Margin
-202.9%
Net Profit Margin
-228.3%
FCF Margin
-270.8%
Adj. FCF Margin
-291.1%
SBC / Revenue
20.3%
SBC Impact (per share)
-7.5%

Returns

Return on Assets
-31.8%
Return on Equity
-68.4%
Return on Invested Capital
-41.9%
Return on Capital Employed
-43.8%
Return on Tangible Assets
-31.8%

Historical Growth (CAGR)

Revenue CAGR 3Y
66.3%
Revenue CAGR 5Y
95.3%
Revenue CAGR 10Y
7.0%
EPS CAGR 3Y
-17.7%
EPS CAGR 5Y
23.0%
EPS CAGR 10Y
16.4%
FCF CAGR 3Y
-16.4%
FCF CAGR 5Y
-18.6%
FCF CAGR 10Y
-0.6%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
12
EPS Growth Next 3Y
1.7%
Revenue Growth Next 3Y
49.3%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.13
EPS Growth Est (next Q)
-8.3%
Revenue Est (next Q)
$4.98M
Revenue Growth Est (next Q)
27.4%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$3
Price Target Upside
61.3%

Cash Flow

Operating Cash Flow
€-49.14M
Free Cash Flow
€-50.29M
Adj. Free Cash Flow
€-54.07M
FCF Per Share
-$0.46
OCF Per Share
-$0.45
OCF/S Ratio
-264.6%

Income Statement

Revenue
€18.57M
Gross Profit
€17.15M
Operating Income
€-43.22M
EBITDA
€-37.69M
Net Income
€-42.4M
EPS (Diluted)
-$0.40
Revenue / Employee
$111.89K
Profit / Employee
$-255.43K
Employees
166

© 2026 bestshares.com. All rights reserved.